I wanted to update you on that in terms of where that team’s at. Now we’re currently at about 70 clinical specialists and we’re continuing to add clinical specialists throughout the country. Our target right now is 100 and we’re unlikely to stop there and we’ll continue to add top talent as we find it throughout the country, but we believe that that expansion is going to also help drive growth.
Joseph Belanoff: Let me just sum that up for you, RK. More doctors prescribing and more patients from each doctor, it’s a trend which really got very strong towards the end of last year and we’re seeing it continue as we speak.
Swayampakula Ramakanth: Is there a price increase included in this?
Joseph Belanoff: Sorry, I couldn’t hear the question.
Sean Maduck: Is there a price increase included in this? There’s not an additional price increase included in the range for this year. We took a price increase on January 01 of this year, 9.49%. We realized about 6.5% of that, but there was no other price increase included in that number.
Swayampakula Ramakanth: Okay. And then on the diabetes population itself, I’m trying to understand a little bit more about how the catalyst data is going to help you out. So to start off, in terms of the percent of population, the diabetes population who are considered difficult to treat, can you give us a number? What percentage of the diabetes population is considered that? And then do you need to do, how do you plan to include that into your label? Is this going to be, do you need to file something or how does it work?
Joseph Belanoff: Yeah. So I think the answer, I think the first question you were asking, RK, was what percentage are difficult to treat diabetics and that’s specifically defined in the protocol, patients who have hemoglobin A1Cs despite having multiple treatments and optimal care. So those patients have been on all of the modern medicine. We’ve been told by our expert, the diabetologists.
Swayampakula Ramakanth: No, that doesn’t give percentage. That just defines who is considered that, but what percentage of population is that?
Joseph Belanoff: I’m getting there. The percentage of the population that, of diabetic population that’s considered to be in that group, difficult to treat diabetics is about a quarter.
Swayampakula Ramakanth: Okay. Thanks.
Joseph Belanoff: And the second question, Sean?
Sean Maduck:
35.05 [ph] :
Operator: And we have a follow-up question from David Amsellem of Piper Sandler.
David Amsellem: Yeah, just a follow-up. So to the extent that the two other generic, Sun and Hikma, enter the market later this year, does that change how you think about your sales expectations or does your $600 million to $630 million contemplate three generic entrants by the second half of this year? Thank you.
Joseph Belanoff: Our guidance includes all those scenarios. And I just want to state that we’ve been thinking about this for a long time and we’ve been prepared for this possibility since 2020. We have a plan in place and we will continue to revise that plan as we receive new market intelligence and as I said before, we’re continuing to invest in our Korlym business and we’re confident in our ability to both grow and protect the share that we have. But yes, all of those scenarios are included.
Operator: And our next question will be coming from Joon Lee of Truist. Your line is open.
Joon Lee: Thanks for the update, and for taking our questions. So 24% of the quarter of 30 million diabetics in the U.S. is an attractive opportunity, but with the Phase 3 grades not having hyperglycemia as an endpoint spelled out, represent a headwind to utilization of melacorlin in diabetics. Or do you think the data from the GRADIENT could be supported there? And also with the orphan pricing of Korlym or relacorilant be prohibited in the utilization and I have a follow up.
Joseph Belanoff: Yeah, Joon, I’m very glad that you asked the first question because it really gives us an opportunity to really clarify what the situation is. Bill, could you please take that one?
William Guyer: So yeah, for the GRACE trial, we have a primary endpoint blood pressure control and a secondary endpoint of glycemic control and so what we do is we have a hierarchy. When we meet our blood pressure control, we plan to then have that as our primary endpoint and therefore, we then move in that hierarchy to glucose control and we expect to meet both of those endpoints and we expect to have a robust response to both hypertension and diabetes control, as well as other comorbidities and based upon meeting all those endpoints, we expect a broad indication for miricorilant.
Joseph Belanoff: I think that’s really an important thing. I’m just going to emphasize that I don’t have anything different to say than Bill said. I want to just underscore that. Our anticipated label for relacorilant is to treat Cushing syndrome. There are many variables that we’re measuring in that and in the hierarchy, hypertension is at the top of the list, but glucose intolerance is on that list, as are many other endpoints that describe Cushing syndrome. It’s probably 20 different endpoints, because Cushing syndrome is a syndrome caused by excess cortisol activity. Cortisol goes everywhere in the body. And many things go wrong when people have Cushing syndrome. Now, you asked a really interesting question about price as we go forward and that’s — that really is something that we really have to think about, as the market enlarges and enlarges and enlarges and we don’t know, as someone I asked, I answered to an earlier question, exactly what the market size is, but we will certainly take all those things into account as we go forward.
One thing I want to just emphasize at this point is that we have not seen a single bit of influence yet from the catalyst information, not a patient. So it’ll be very interesting to see where that goes over time.
Joon Lee: All right, looking forward to the full data. And on generic, are you seeing any impact to Korlym since Teva was generic launch six, eight weeks ago and have you or do you plan to institute any new sales strategy in response to generic launch? Thank you.
Joseph Belanoff: I’m going to give you back to Sean for that question.
Sean Maduck: Yeah, no, June, thanks for the question. There has been no impact to our business since Teva announced its launch. We have seen no evidence of generic Mifepristone in the marketplace and we’re monitoring daily. And to your second question, I’m not going to go into any specifics, but again, we’ve been prepared. We have a plan in place and more to follow.
Operator: Thank you. There are no further questions in the queue.
Atabak Mokari: All right. Well, thank you, everybody. And look forward to three months.
